Overview

The Effect of Pramlintide on Meal Time Insulin Bolus

Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
The primary objective is to establish the mean percentage of change in the insulin-to-carbohydrate ratio due to pramlintide treatment once a maximum tolerated dose or 6 mcg before each meal is reached. The secondary objective is to establish which insulin bolus wave form is associated with the lowest post-bolus without hypoglycemia in subjects treated with maximum pramlintide dosage.
Phase:
N/A
Details
Lead Sponsor:
Diabetes Care Center
Collaborator:
Amylin Pharmaceuticals, LLC.
Treatments:
Insulin
Insulin, Globin Zinc
Islet Amyloid Polypeptide
Pramlintide